ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,168.20
-1.70%
S&P ASX All Technology
3,794.30
-2.54%
Brent Oil
72.935
0.27%
US Dollar vs AUD
1.60002
-0.73%
Bitcoin
101,923.55
1.86%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Mesoblast Limited (MESO)

  7. Mesoblast Limited (MESO) News

MESO

Mesoblast (MESO)

Mesoblast Limited
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MESO
DateTimeSourceHeadlineSymbolCompany
19/12/202411:08GlobeNewswire Inc.Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) TherapyNASDAQ:MESOMesoblast Limited
18/12/202423:30GlobeNewswire Inc.Mesoblast to be Added to Nasdaq Biotechnology IndexNASDAQ:MESOMesoblast Limited
14/12/202408:04Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:MESOMesoblast Limited
10/12/202408:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
05/12/202410:32GlobeNewswire Inc.FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
03/12/202410:20GlobeNewswire Inc.Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With InflammationNASDAQ:MESOMesoblast Limited
18/11/202422:47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
31/10/202410:11GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024NASDAQ:MESOMesoblast Limited
10/10/202406:42Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MESOMesoblast Limited
30/09/202410:55GlobeNewswire Inc.Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product LaunchNASDAQ:MESOMesoblast Limited
29/08/202421:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
29/08/202409:27GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024NASDAQ:MESOMesoblast Limited
28/08/202409:25GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
31/07/202411:13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024NASDAQ:MESOMesoblast Limited
23/07/202421:53GlobeNewswire Inc.FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
22/07/202410:45GlobeNewswire Inc.Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back PainNASDAQ:MESOMesoblast Limited
09/07/202410:37GlobeNewswire Inc.Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
01/07/202415:55GlobeNewswire Inc.Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next WeekNASDAQ:MESOMesoblast Limited
03/06/202410:23GlobeNewswire Inc.Mesoblast Corporate Presentation at Investor ConferenceNASDAQ:MESOMesoblast Limited
30/04/202411:05GlobeNewswire Inc.Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024NASDAQ:MESOMesoblast Limited
27/03/202400:25AllPennyStocks.comFDA Commentary Sends Biotech Soaring During Premarket HoursNASDAQ:MESOMesoblast Limited
26/03/202413:34GlobeNewswire Inc.United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
14/03/202410:30GlobeNewswire Inc.Mesoblast Successfully Completes Placement and Accelerated Entitlement OfferNASDAQ:MESOMesoblast Limited
11/03/202410:54GlobeNewswire Inc.United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)NASDAQ:MESOMesoblast Limited
29/02/202409:57GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023NASDAQ:MESOMesoblast Limited
26/02/202423:00GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
15/02/202411:46GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
01/02/202413:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
31/01/202413:13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023NASDAQ:MESOMesoblast Limited
19/01/202411:28Dow Jones NewsMesoblast Gets FDA's Special Pediatric Designation for Revascor Heart TreatmentNASDAQ:MESOMesoblast Limited
 Showing the most relevant articles for your search:NASDAQ:MESO

Your Recent History

ASX
BHP
BHP
FTSE
UKX
FTSE 100
ASX
QBE
QBE Insurance
SPI
SP500
S&P 500
ASX
TLS
Telstra
NYSE
XOM
Exxon Mobil
ASX
XFL
S&P ASX 50
NYSE
VZ
Verizon Communications
ASX
MQG
Macquarie
PM
XAUUSD
Gold vs US Dollar
NASDAQ
QQQ
Invesco QQQ Trust Series 1
ASX
ANZ
Australia And New Zealan...
ASX
WBC
Westpac Banking
NYSE
NKE
Nike
CCOM
SILVER
SILVER
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads